PL2361090T3 - Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo - Google Patents

Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo

Info

Publication number: PL2361090T3
Authority: PL; Poland
Prior art keywords: vomiting; compositions; centrally mediated; treating; nausea
Prior art date: 2009-11-18

Application number

PL10805301T

Other languages

English (en)

Inventor

Fabio Trento

Sergio Cantoreggi

Giorgia Rossi

Roberta Cannella

Daniele Bonadeo

Riccardo Braglia

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-18

Filing date

2010-11-18

Publication date

2014-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2361090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-18 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2014-10-31 Publication of PL2361090T3 publication Critical patent/PL2361090T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Paints Or Removers (AREA)

PL10805301T 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo PL2361090T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US26247009P	2009-11-18	2009-11-18
US38270910P	2010-09-14	2010-09-14
EP10805301.8A EP2361090B1 (en)	2009-11-18	2010-11-18	Compositions for treating centrally mediated nausea and vomiting
PCT/IB2010/003106 WO2011061622A1 (en)	2009-11-18	2010-11-18	Compositions for treating centrally mediated nausea and vomiting

Publications (1)

Publication Number	Publication Date
PL2361090T3 true PL2361090T3 (pl)	2014-10-31

Family

ID=43608757

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL10805301T PL2361090T3 (pl)	2009-11-18	2010-11-18	Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo
PL14151678T PL2722044T3 (pl)	2009-11-18	2010-11-18	Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo
PL14151683T PL2722045T3 (pl)	2009-11-18	2010-11-18	Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL14151678T PL2722044T3 (pl)	2009-11-18	2010-11-18	Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo
PL14151683T PL2722045T3 (pl)	2009-11-18	2010-11-18	Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo

Country Status (40)

Country	Link
US (1)	US12042494B2 (pl)
EP (3)	EP2361090B1 (pl)
JP (1)	JP5890780B2 (pl)
KR (1)	KR101615108B1 (pl)
CN (6)	CN107050455B (pl)
AP (1)	AP3083A (pl)
AU (1)	AU2010320598B2 (pl)
BR (1)	BR112012011485B1 (pl)
CA (1)	CA2778301C (pl)
CL (1)	CL2012001276A1 (pl)
CO (1)	CO6551693A2 (pl)
CR (1)	CR20120216A (pl)
CU (1)	CU24048B1 (pl)
CY (1)	CY1118062T1 (pl)
DK (2)	DK2722045T3 (pl)
DO (1)	DOP2012000138A (pl)
EA (1)	EA026815B1 (pl)
EC (1)	ECSP12011907A (pl)
ES (4)	ES2623503T3 (pl)
GE (1)	GEP20156226B (pl)
GT (1)	GT201200156A (pl)
HK (2)	HK1214148A1 (pl)
HR (3)	HRP20140759T1 (pl)
HU (1)	HUE029677T2 (pl)
IL (1)	IL219576A (pl)
LT (1)	LT2722045T (pl)
MA (1)	MA33810B1 (pl)
MX (1)	MX2012005347A (pl)
MY (1)	MY159393A (pl)
NI (1)	NI201200090A (pl)
NZ (1)	NZ599439A (pl)
PE (1)	PE20121483A1 (pl)
PH (1)	PH12012500887A1 (pl)
PL (3)	PL2361090T3 (pl)
PT (2)	PT2722045T (pl)
RS (2)	RS55206B1 (pl)
SI (2)	SI2361090T1 (pl)
SM (1)	SMT201400112B (pl)
TN (1)	TN2012000170A1 (pl)
WO (1)	WO2011061622A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
CN107050455B (zh)	2009-11-18	2020-09-29	赫尔森保健股份公司	用于治疗中枢介导的恶心及呕吐的组合物及方法
DK2729147T3 (en)	2011-07-04	2017-12-18	Irbm - Science Park S P A	NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
HUE030811T2 (hu) *	2011-10-18	2017-05-29	Helsinn Healthcare Sa	Netupitant és palonosetron terápiás kombinációi
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en)	2011-11-29	2016-08-02	Helsinn Healthcare Sa	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) *	2012-07-05	2017-10-24	海思科医药集团股份有限公司	一种治疗呕吐的药物组合物
ES2824552T3 (es)	2015-03-04	2021-05-12	Vanda Pharmaceuticals Inc	Método de tratamiento con tradipitant
CN106902086B (zh) *	2015-12-23	2020-10-20	江苏恒瑞医药股份有限公司	一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) *	2016-11-01	2016-12-14	Acacia Pharma Ltd	method
GB201702250D0 (en)	2017-02-10	2017-03-29	Acacia Pharma Ltd	Method
CN108721214B (zh) *	2017-04-14	2020-06-16	和龙	奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) *	2017-05-15	2018-11-23	和龙	奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) *	2017-07-04	2019-01-15	南京诺瑞特医药科技有限公司	含有奈妥吡坦的微乳制剂
HUE071527T2 (hu) *	2017-11-17	2025-09-28	Vanda Pharmaceuticals Inc	Tradipitant gasztroparézis kezelésében történõ alkalmazásra
CN111670035A (zh) *	2018-02-02	2020-09-15	尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号）	经口制剂及其用途
EP4633608A1 (en)	2022-12-12	2025-10-22	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Fixed dose combination comprising netupitant and palonosetron
CN120693151A (zh)	2022-12-12	2025-09-23	阿尔弗雷德.E.蒂芬巴赫尔有限责任两合公司	包括奈妥匹坦和帕洛诺司琼的固定剂量组合

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA909529B (en)	1989-11-28	1992-08-26	Syntex Inc	New tricyclic compounds
US5510486A (en)	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en)	1995-11-10	2001-10-02	The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland	Calixarenes and their use for sequestration of metals
ATE277905T1 (de)	1999-02-24	2004-10-15	Hoffmann La Roche	4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
WO2002006236A1 (en)	2000-07-14	2002-01-24	F. Hoffmann-La Roche Ag	N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
KR100602299B1 (ko)	2000-12-14	2006-07-14	에프. 호프만-라 로슈 아게	자가 유화성 지질 매트릭스
CA2505990C (en)	2002-11-15	2009-05-19	Helsinn Healthcare S.A.	Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en)	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formations of balloonosterone
MY143789A (en) *	2003-02-18	2011-07-15	Helsinn Healthcare Sa	Use of palonosetron treating post- operative nausea and vomiting
WO2004091622A1 (en) *	2003-04-08	2004-10-28	Progenics Pharmaceuticals, Inc.	The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
JP2008531509A (ja)	2005-02-25	2008-08-14	エフ．ホフマン−ラロシュアーゲー	医薬品成分の改良された分散性を有する錠剤
US7479312B2 (en)	2005-07-07	2009-01-20	Konica Minolta Opto, Inc.	Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
US8138188B2 (en)	2006-02-23	2012-03-20	Pfizer Inc.	Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2008049552A1 (en) *	2006-10-24	2008-05-02	Helsinn Healthcare S.A.	Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
WO2009005673A1 (en) *	2007-06-28	2009-01-08	Schering Corporation	Anti-igf1r
JP2011505873A (ja) *	2007-12-18	2011-03-03	シェーリングコーポレイション	抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
CN107050455B (zh)	2009-11-18	2020-09-29	赫尔森保健股份公司	用于治疗中枢介导的恶心及呕吐的组合物及方法

2010
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en not_active Ceased
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 PH PH1/2012/500887A patent/PH12012500887A1/en unknown
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/en active
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
- 2010-11-18 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active Active
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 RS RSP20140423 patent/RS53491B1/sr unknown
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
2014
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
2016
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active

Also Published As

Publication number	Publication date
NZ599439A (en)	2014-06-27
CU24048B1 (es)	2014-12-26
SMT201400112B (it)	2014-11-10
CA2778301A1 (en)	2011-05-26
PL2722044T3 (pl)	2017-08-31
PE20121483A1 (es)	2012-12-02
IL219576A0 (en)	2012-06-28
TN2012000170A1 (en)	2013-12-12
NI201200090A (es)	2012-11-13
CN106512010A (zh)	2017-03-22
BR112012011485A2 (pt)	2018-04-03
HRP20170419T1 (hr)	2017-06-02
HRP20140759T1 (hr)	2014-10-24
DK2722045T3 (en)	2016-10-24
KR101615108B1 (ko)	2016-05-12
AU2010320598A1 (en)	2012-06-14
EA026815B1 (ru)	2017-05-31
EA201290356A1 (ru)	2012-12-28
SI2361090T1 (sl)	2014-09-30
GEP20156226B (en)	2015-01-26
CL2012001276A1 (es)	2012-12-07
ES2494015T3 (es)	2014-09-12
HK1214147A1 (zh)	2016-07-22
IL219576A (en)	2017-08-31
RS55206B1 (sr)	2017-01-31
US12042494B2 (en)	2024-07-23
CN107050455A (zh)	2017-08-18
EP2361090A1 (en)	2011-08-31
EP2722044A1 (en)	2014-04-23
AP3083A (en)	2015-01-31
CN107050455B (zh)	2020-09-29
MA33810B1 (fr)	2012-12-03
HK1214148A1 (zh)	2016-07-22
PL2722045T3 (pl)	2017-03-31
DK2361090T3 (da)	2014-08-25
BR112012011485B1 (pt)	2021-06-29
HUE029677T2 (hu)	2017-03-28
ES2559475T3 (es)	2016-02-12
CN104856998A (zh)	2015-08-26
CR20120216A (es)	2012-07-24
PH12012500887A1 (en)	2016-08-26
EP2722044B1 (en)	2017-01-04
AP2012006278A0 (en)	2012-06-30
JP2013511507A (ja)	2013-04-04
WO2011061622A1 (en)	2011-05-26
CO6551693A2 (es)	2012-10-31
PT2722045T (pt)	2016-10-18
EP2727590A1 (en)	2014-05-07
MY159393A (en)	2016-12-30
EP2727590B1 (en)	2015-10-21
CY1118062T1 (el)	2017-06-28
CN102655864A (zh)	2012-09-05
ES2623503T3 (es)	2017-07-11
EP2361090B1 (en)	2014-05-21
CN104856999A (zh)	2015-08-26
CU20120078A7 (es)	2012-10-15
CA2778301C (en)	2016-06-14
GT201200156A (es)	2014-03-27
MX2012005347A (es)	2012-08-03
HRP20161277T1 (hr)	2016-11-18
PT2361090E (pt)	2014-09-03
ES2595077T3 (es)	2016-12-27
KR20120101456A (ko)	2012-09-13
SI2722045T1 (sl)	2017-02-28
AU2010320598B2 (en)	2016-06-16
US20230263799A1 (en)	2023-08-24
RS53491B1 (sr)	2015-02-27
LT2722045T (lt)	2016-09-26
CN106421793A (zh)	2017-02-22
JP5890780B2 (ja)	2016-03-22
ECSP12011907A (es)	2012-10-30
DOP2012000138A (es)	2012-11-15
CN106421793B (zh)	2023-06-16

Publication	Publication Date	Title
AP3083A (en)	2015-01-31	Compositions for treating centrally mediated nausea and vomiting
IL245734A0 (en)	2016-06-30	Methods and preparations to prevent abuse
IL215932A0 (en)	2011-12-29	Compositions and methods for treating burns
EP2429584A4 (en)	2013-02-20	TREATMENT PROCEDURE AND COMPOSITIONS
EP2483221A4 (en)	2015-05-13	FERTILIZER COMPOSITIONS AND METHOD THEREFOR
EP2722045A3 (en)	2014-05-07	Compositions for treating centrally mediated nausea and vomiting
IL239918A0 (en)	2015-08-31	Preparations for the treatment of colitis
SI3812360T1 (sl)	2024-02-29	Monoklorotrifluoropropenske spojine in sestavki ter postopki, ki jih uporabljajo
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
GB0903299D0 (en)	2009-04-08	Composition and methods
GB0912468D0 (en)	2009-08-26	Composition and method
EP2490536A4 (en)	2013-04-17	COMPOSITION AND METHOD
EP2294198A4 (en)	2011-10-19	METHODS AND COMPOSITIONS FOR ENHANCING PLANTS
WO2011057220A9 (en)	2011-08-18	Compositions and methods for treating lymphoma
GB0901494D0 (en)	2009-03-11	Compositions and Methods
EP2512504A4 (en)	2013-06-19	COMPOSITION AND THERAPEUTIC METHOD
IL217764A0 (en)	2012-03-29	Methods and compositions for treating leukemia
PL2263454T3 (pl)	2017-07-31	Kompozycja uzdatniająca
GB0901667D0 (en)	2009-03-11	Composition and method
ZA201203174B (en)	2013-02-27	Compositions for treating centrally mediated nausea and vomiting
HK1166283A (en)	2012-10-26	Methods and compositions for treating leukemia
HK1164745A (en)	2012-09-28	Methods and compositions for treating neuropathies
GB0912714D0 (en)	2009-08-26	Composition and process
GB0909720D0 (en)	2009-07-22	Compositions and methods
GB0903913D0 (en)	2009-04-22	Compositions and methods